Related Experiment Video

Updated: Jun 20, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet
13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum (Clove) and Cuminun cyminum (Cumin) on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Anti-obesity effects of xanthohumol plus guggulsterone in 3T3-L1 adipocytes

Srujana Rayalam1, Jeong-Yeh Yang, Mary Anne Della-Fera

  • 1Department of Animal & Dairy Science, University of Georgia, Athens, Georgia 30602-2771, USA.

Journal of Medicinal Food
|September 9, 2009
PubMed

Insights

The combination of Xanthohumol (XN) and guggulsterone (GS) significantly enhances anti-obesity effects by potentiating apoptosis and inhibiting adipogenesis in 3T3-L1 adipocytes. This synergistic action is more effective than either compound alone.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Xanthohumol (XN) and guggulsterone (GS) are known to inhibit adipogenesis and induce apoptosis in adipocytes.
  • Investigating the combined effects of XN and GS on adipocyte function is crucial for understanding their potential therapeutic applications.

Purpose of the Study:

  • To investigate the synergistic effects of Xanthohumol (XN) and guggulsterone (GS) on apoptosis and adipogenesis in 3T3-L1 adipocytes.
  • To evaluate the anti-obesity potential of the XN + GS combination.

Main Methods:

  • 3T3-L1 adipocytes were treated with XN and GS individually and in combination.
  • Cell viability, apoptosis, caspase-3/7 activation, and lipolysis were assessed.
  • Western blot analysis was used to examine Bax and Bcl-2 expression and adipocyte-specific proteins.

Main Results:

  • The XN + GS combination significantly enhanced apoptosis induction and decreased cell viability compared to individual treatments.
  • Combined treatment potentiated caspase-3/7 activation and modulated Bax/Bcl-2 expression.
  • XN + GS markedly reduced lipid accumulation and down-regulated adipocyte-specific proteins, with enhanced lipolysis stimulation.

Conclusions:

  • The combination of Xanthohumol and guggulsterone exhibits synergistic anti-obesity effects.
  • The XN + GS combination is more potent in inhibiting adipogenesis and promoting apoptosis than individual compounds.

More Related Videos

Isolation of Adipose Tissue Immune Cells07:09

Isolation of Adipose Tissue Immune Cells

Published on: May 22, 2013

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...